{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T05:30:37Z","timestamp":1781933437160,"version":"3.54.5"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81301509"],"award-info":[{"award-number":["81301509"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2016-4-1141"],"award-info":[{"award-number":["2016-4-1141"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.diagmicrobio.2019.02.012","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T02:25:50Z","timestamp":1550543150000},"page":"361-364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis"],"prefix":"10.1016","volume":"94","author":[{"given":"Yu","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaojing","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengmin","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naihui","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2019.02.012_bb0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.diagmicrobio.2019.02.012_bb0010","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(10)70139-0","article-title":"Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis","volume":"10","author":"Caminero","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.02.012_bb0015","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMp1314385","article-title":"FDA approval of bedaquiline\u2014the benefit\u2013risk balance for drug-resistant tuberculosis","volume":"371","author":"Cox","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2019.02.012_bb0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/resp.13143","article-title":"Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?","volume":"23","author":"Dheda","year":"2017","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2019.02.012_bb0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cmi.2016.10.008","article-title":"Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis","volume":"23","author":"Dheda","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2019.02.012_bb0030","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/AAC.06126-11","article-title":"Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance","volume":"56","author":"Diacon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.02.012_bb0035","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/S0140-6736(10)60410-2","article-title":"Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis","volume":"375","author":"Gandhi","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.diagmicrobio.2019.02.012_bb0040","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1086\/653115","article-title":"Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis","volume":"51","author":"Jacobson","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.02.012_bb0045","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ajo.2006.06.006","article-title":"The in vitro impact of moxifloxacin and gatifloxacin concentration (0.5% vs 0.3%) and the addition of benzalkonium chloride on antibacterial efficacy","volume":"142","author":"Kowalski","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.diagmicrobio.2019.02.012_bb0050","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02627-16","article-title":"In vitro activity of bedaquiline against nontuberculous mycobacteria in China","volume":"61","author":"Pang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.02.012_bb0055","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00900-17","article-title":"In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis from Beijing, China","author":"Pang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.02.012_bb0060","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1183\/13993003.01891-2015","article-title":"Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence","volume":"47","author":"Pontali","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.diagmicrobio.2019.02.012_bb0065","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1128\/AAC.01601-09","article-title":"In vitro interactions between new antitubercular drug candidates SQ109 and TMC207","volume":"54","author":"Reddy","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.02.012_bb0070","series-title":"Introduction of bedaquiline for the treatment of multidrug-resistant tuberculosis at country level","author":"World Health Organization (WHO)","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2019.02.012_bb0075","series-title":"Global tuberculosis report 2016","author":"World Health Organization (WHO)","year":"2016"},{"key":"10.1016\/j.diagmicrobio.2019.02.012_bb0080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijantimicag.2014.09.012","article-title":"In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates","volume":"45","author":"Zhang","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2019.02.012_bb0085","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tube.2015.07.003","article-title":"Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates","volume":"95","author":"Zou","year":"2015","journal-title":"Tuberculosis (Edinb)"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889319301786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889319301786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T14:41:46Z","timestamp":1569076906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889319301786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0732889319301786"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.02.012","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}